NCT02423577View on ClinicalTrials.gov

Safety and Protective Efficacy of FF-3 Dry Powder in Healthy Subjects Infected With Influenza Challenge Strain

PHASE2CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Influenza
Interventions
DRUG

FF-3 dry powder

FF-3 dry powder administered by nasal inhalation

DRUG

Placebo

Placebo dry powder administered by nasal inhalation

Trial Locations (1)

Unknown

Quintiles Drug Research Unit, London

Sponsors
All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Autoimmune Technologies, LLC

INDUSTRY

NCT02423577 - Safety and Protective Efficacy of FF-3 Dry Powder in Healthy Subjects Infected With Influenza Challenge Strain | Biotech Hunter | Biotech Hunter